(NASDAQ: ABUS) Arbutus Biopharma's forecast annual revenue growth rate of 12.59% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 50.87%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.79%.
Arbutus Biopharma's revenue in 2025 is $6,742,000.On average, 3 Wall Street analysts forecast ABUS's revenue for 2025 to be $1,068,733,103, with the lowest ABUS revenue forecast at $1,023,255,099, and the highest ABUS revenue forecast at $1,121,790,775. On average, 1 Wall Street analysts forecast ABUS's revenue for 2026 to be $1,595,519,988, with the lowest ABUS revenue forecast at $1,595,519,988, and the highest ABUS revenue forecast at $1,595,519,988.
In 2027, ABUS is forecast to generate $1,754,693,003 in revenue, with the lowest revenue forecast at $1,754,693,003 and the highest revenue forecast at $1,754,693,003.